Arrowhead Pharmaceuticals Files Suit Against Ionis Pharmaceuticals Over Patent Dispute on Investigational Drug Plozasiran
Arrowhead Pharmaceuticals Inc. has filed a lawsuit against Ionis Pharmaceuticals Inc. in the U.S. District Court for Delaware, seeking to declare Ionis’s U.S. Patent No. 9,593,333 invalid and asserting that its investigational drug plozasiran does not infringe on this patent. This action follows Ionis's threats of litigation over alleged patent infringement, which Arrowhead claims are unfounded. Arrowhead is committed to developing new treatments for familial chylomicronemia syndrome and plans to defend its position vigorously in court.
Arrowhead Pharmaceuticals Inc. has filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals Inc. The complaint seeks to establish that Ionis’s U.S. Patent No. 9,593,333 is invalid and that Arrowhead’s investigational drug plozasiran, currently under FDA review, does not infringe on this patent. This legal action follows threats of litigation from Ionis regarding alleged patent infringement. Arrowhead asserts that these allegations are baseless and maintains that its development of plozasiran and its proprietary platform were accomplished independently. The company emphasizes its commitment to providing new treatment options for patients with familial chylomicronemia syndrome (FCS), a rare and severe disease. Arrowhead is confident in its position and plans to vigorously defend its claims in court. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911154263) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
